Abstract Body

Background: Therapeutic strategies which target the latent HIV-1 reservoir in resting CD4+ T cells of infected-individuals are always administered in the presence of combination antiretroviral (ART) therapy. In this study, we evaluated whether the different therapeutic classes of ARV drugs impacted HIV-1 latency reversal.

Methods: Latency reversal was evaluated in a primary cell model of latency that utilizes direct infection of resting CD4+ T cells. Two hours prior to addition of anti-CD3/CD28 monoclonal antibodies, cells were treated with an entry inhibitor (AMD3100 or maraviroc), a PI (atazanavir, darunavir), NRTI (lamivudine), NNRTI (rilpivirine, efavirenz) or INSTI (raltegravir). Controls included cells that were exposed only to antibody or the ARVs. Seven days post antibody administration, cell-associated HIV-1 DNA and extracellular virion production were quantified. T cell activation and viability were assessed by flow cytometry.

Results: NNRTIs were found to decrease both R5- and X4-tropic HIV-1 production (by ≥ 1-log fold-change) in resting CD4+ T cells exposed to anti-CD3/CD28 monoclonal antibodies. This decrease was not due to toxicity, or changes in T cell activation in the presence or absence of NNRTI as assessed by CD25, CD69 or HLA-DR expression. In contrast, none of the other ARVs, including PIs which target the late stages of HIV-1 replication, had a significant impact on virus production. Further analysis in a cell line model of HIV-1 latency (J89GFP cells) revealed that the NNRTIs did not interfere with HIV-1 gene transcription or translation. Instead, consistent with published studies, we propose that the NNRTIs enhance premature activation of HIV-1 PR which results in intracellular processing of Gag and Gag-Pol leading to decreased viral particle production.

Conclusions: NNRTIs reduce HIV-1 production from latently infected cells. Ex vivo studies that use NNRTIs to prevent virus spread or cells from donors on NNRTI containing regimens should be cautiously interpreted.